Streamlined Oncology Calculators & Survival Analysis
For clinical decision & research support.
Browse by Specialty
Myeloma Master Panel (R2-ISS & Frailty)
Integrates Disease Biology (R2-ISS) and Patient Fitness (IMWG) for treatment selection.
Febrile Neutropenia Triage
Combined MASCC and CISNE scores for risk stratification.
Palliative Survival Prediction
Survival estimates using PaP and PPI scores.
Liver & HCC Master Panel
Simultaneous calculation of Child-Pugh, ALBI, MELD-Na, BCLC, HKLC, and Milan Criteria.
Lung Nodule Malignancy Risk Panel
Comparison of Mayo, Brock (PanCan), and Herder models for pulmonary nodules.
Prostate Cancer Risk Stratification (NCCN & CAPRA)
Unified assessment using NCCN Guidelines (v4.2024), CAPRA Score, and Epstein Criteria.
Renal Cell Carcinoma (RCC) Prognosis Panel
Combined IMDC (Heng) and MSKCC (Motzer) risk stratification for metastatic RCC.
Lymphoma (DLBCL) Prognosis Panel
Combined Classic IPI and NCCN-IPI for Diffuse Large B-Cell Lymphoma.
ECOG Performance Status
Derives performance status from functional ability (Activity, Self-care, Confinement).
Body Surface Area (BSA)
Calculates BSA using Du Bois or Mosteller formulas.
Karnofsky Performance Status (KPS)
Functional assessment scale (0-100) determining patient ability to perform ordinary tasks.
WHO Performance Status
World Health Organization Performance Status scale.
TNM Staging Recorder (Universal)
A tool to record T, N, and M values. Note: Exact staging is site-specific.
Charlson Comorbidity Index
Predicts 10-year mortality based on comorbid conditions and age.
RMH Score (Phase I Trials)
Royal Marsden Hospital prognostic score for Phase I trial patients.
Khorana Score (VTE Risk)
Predicts risk of Venous Thromboembolism in cancer patients starting chemotherapy.
CUPI Score (Cancer of Unknown Primary)
Prognostic index for carcinoma of unknown primary site.
EBV-DNA Prognostic Score (NPC)
Refines NPC prognosis using TNM stage and pre-treatment EBV DNA.
MSKCC Pancreatic Cancer Nomogram
Predicts survival after resection of pancreatic adenocarcinoma.
Fistula Risk Score (FRS)
Predicts Pancreatic Fistula (CR-POPF) risk after pancreaticoduodenectomy.
MSKCC Gastric Cancer Nomogram
Predicts survival after R0 resection for gastric cancer.
JGCA Risk Classifier (EGC Curability)
Determines curability of Early Gastric Cancer (EGC) by ESD.
Modified Glasgow Prognostic Score (mGPS)
Prognostic score based on systemic inflammation (CRP and Albumin).
Fong Clinical Risk Score (CRS)
Predicts recurrence after resection of colorectal liver metastases.
Peritoneal Carcinomatosis Index (PCI)
Quantifies tumor burden in the peritoneal cavity (Sugarbaker).
NIH GIST Risk (Miettinen)
Predicts recurrence risk for GIST based on size and mitotic count.
AFIP GIST Risk (Miettinen)
Refined GIST risk assessment including tumor location.
Oncotype DX® Colon Recurrence Score
Predicts recurrence risk in Stage II/III colon cancer.
Stage II Colon Cancer Risk Assessment
Identifies high-risk features for adjuvant chemotherapy.
PSDSS (Prostate Cancer-Specific Survival)
Peritoneal Surface Disease Severity Score (Pelz/Sugarbaker).
GRIm Score
Gustave Roussy Immune Score for immunotherapy prognosis.
LIPI Score (Lung Immune)
Lung Immune Prognostic Index for NSCLC immunotherapy outcomes.
Lung-RADS™ v2022
ACR Lung Imaging Reporting and Data System for screening CTs.
Small Cell Lung Cancer Staging (VALSG)
Veterans Administration Lung Study Group (VALSG) staging for SCLC.
Solitary Pulmonary Nodule Malignancy Risk (Mayo)
Estimates probability of malignancy in a solitary pulmonary nodule (SPN).
Herder Model (Pulmonary Nodule)
Malignancy risk for pulmonary nodules incorporating PET-CT results.
Brock (PanCan) Nodule Risk
Estimates malignancy probability in pulmonary nodules (McWilliams/PanCan).
PLCOm2012 Lung Cancer Risk
Predicts 6-year risk of lung cancer in ever-smokers.
Masaoka-Koga Staging (Thymoma)
Standard staging system for Thymic Malignancies.
Mesothelioma EORTC Prognostic Index
Predicts survival in Malignant Pleural Mesothelioma (MPM).
Mesothelioma CALGB Score
Cancer and Leukemia Group B (CALGB) prognostic scoring.
WHO CNS Tumor Grade (2021)
Grading system for Central Nervous System tumors.
RPA (Brain Metastases)
RTOG Recursive Partitioning Analysis for brain mets survival.
GPA (Graded Prognostic Assessment)
Original GPA score for brain metastases prognosis.
Diagnosis-Specific GPA (Brain Mets)
Updated GPA scores by primary site (Lung, Breast, Melanoma, Renal, GI).
Tokuhashi Score (Spine Mets)
Predicts survival for metastatic spine tumors to guide surgery.
Tomita Score (Spine Mets)
Prognostic scoring for surgical strategy in spinal metastases.
SINS (Spinal Instability)
Spinal Instability Neoplastic Score for tumor-related instability.
NESMS (Epidural Spinal Cord)
New England Spinal Metastasis Score for post-op survival.
Mirels Score (Fracture Risk)
Predicts risk of pathologic fracture in long bones.
Bauer Score (Bone Mets)
Prognostic score for metastatic spine surgery survival.
Katagiri Score (Bone Mets)
Prognostic score for patients with bone metastases.
FNCLCC Grade (Soft Tissue Sarcoma)
Histologic grading of soft tissue sarcomas (French Federation).
Enneking Staging (Bone/Sarcoma)
Surgical staging system for musculoskeletal sarcomas.
HLH-2004 Diagnostic Criteria
Diagnostic criteria for Hemophagocytic Lymphohistiocytosis.
HScore for HLH
Estimates probability of Hemophagocytic Lymphohistiocytosis (HLH).
LCH Risk Organ Classification
Stratifies LCH into Single/Multi-system and Risk Organ status.
Ann Arbor Staging (Histiocytic Sarcoma)
Anatomic staging analogous to lymphoma for Histiocytic Sarcoma.
Weiss Score (Adrenal)
Differentiates benign adrenocortical adenoma from carcinoma (ACC).
PASS Score (Pheochromocytoma)
Pheochromocytoma of the Adrenal Gland Scaled Score.
NET Grade / WHO 2019
Histological grading of Neuroendocrine Tumors (NETs).
MASCC Risk Index
Identifies low-risk patients with febrile neutropenia.
CARG Toxicity Score (Geriatric)
Predicts Grade 3-5 chemotherapy toxicity in older adults (≥65y).
G8 Screening Tool
Screening tool to identify older cancer patients requiring full geriatric assessment.
CISNE Score (Febrile Neutropenia)
Clinical Index of Stable Febrile Neutropenia.
Opioid Rotation & OME Calculator
Evidence-based conversion with NCCN safety pearls for cancer pain rotation and breakthrough dosing.
ESAS-r Symptom Score
Edmonton Symptom Assessment System (Revised) for symptom burden.
PaP Score (Palliative Prognosis)
Predicts 30-day survival in palliative care patients.
Palliative Prognostic Index (PPI)
Predicts survival (weeks vs months) in terminal cancer.
NCCN-IPI (Lymphoma)
Enhanced prognostic index for Diffuse Large B-Cell Lymphoma.
CLL-IPI
International Prognostic Index for Chronic Lymphocytic Leukemia.
MIPI (Mantle Cell Lymphoma)
Mantle Cell Lymphoma International Prognostic Index.
IPS (Hodgkin Lymphoma)
Hasenclever International Prognostic Score for Advanced HL.
IPS-7 (Adult Hodgkin Lymphoma)
Prognostic score for advanced-stage (III-IV) HL in adults.
CHIPS (Childhood Hodgkin Score)
The standard prognostic score for pediatric and adolescent Hodgkin Lymphoma.
DIPSS (Myelofibrosis)
Dynamic International Prognostic Scoring System for Primary Myelofibrosis.
DIPSS-Plus (Myelofibrosis)
Refined prognosis for Primary Myelofibrosis (incorporates karyotype).
IPSSWM (Waldenström)
International Prognostic Scoring System for Waldenström Macroglobulinemia.
IPSET-Thrombosis (Essential Thrombocythemia)
Predicts thrombosis risk in Essential Thrombocythemia (ET).
ELTS Score (CML)
EUTOS Long-Term Survival score for CML.
SANZ Risk Score (APL)
Stratifies risk in Acute Promyelocytic Leukemia (APL).
HCT-CI (Transplant Risk)
Hematopoietic Cell Transplantation-Specific Comorbidity Index.
R-ISS (Multiple Myeloma)
Revised International Staging System for Multiple Myeloma.
FLIPI (Follicular Lymphoma)
Follicular Lymphoma International Prognostic Index.
IPSS-R for MDS
Revised International Prognostic Scoring System for Myelodysplastic Syndromes.
International Prognostic Index (IPI)
International Prognostic Index for DLBCL.
ALBI Score
Albumin-Bilirubin Grade for Hepatocellular Carcinoma (HCC) risk assessment.
ALBI-T Score
Tumor-integrated ALBI grade for HCC prognosis.
BCLC Staging System (2022 Update)
Barcelona Clinic Liver Cancer staging (2022 update).
HKLC Staging System
Hong Kong Liver Cancer staging for treatment stratification.
CNLC Staging (China)
China Liver Cancer staging system.
JIS Score (Japan Integrated Staging)
Combines Child-Pugh grade and Japanese TNM stage.
Child-Pugh Score
Estimates severity of cirrhosis and expected survival rate.
MELD Score
Model for End-Stage Liver Disease (Original) for liver transplant prioritization.
Milan Criteria
Determines eligibility for liver transplantation in HCC patients.
CLIP Score
Cancer of the Liver Italian Program score for HCC prognosis.
LI-RADS® v2018 (CT/MRI)
Standardized reporting for liver lesions in at-risk patients.
IMDC (Heng) Risk Score
Prognostic model for metastatic Renal Cell Carcinoma (mRCC).
MSKCC (Motzer) Score
Prognostic model for metastatic Renal Cell Carcinoma (mRCC).
Leibovich Score (RCC)
Predicts metastasis-free survival for clear cell RCC after nephrectomy.
SSIGN Score (Mayo)
Stage, Size, Grade, and Necrosis score for RCC prognosis.
UISS (UCLA Integrated Staging)
Prognostic system for localized Renal Cell Carcinoma.
BI-RADS Score (Breast)
Breast Imaging-Reporting and Data System.
Nottingham Prognostic Index (NPI)
Prognostic index for invasive breast cancer.
MSKCC DCIS Nomogram
Estimates local recurrence risk after breast-conserving surgery for DCIS.
Van Nuys Prognostic Index (USC-VNPI)
Prognostic index for Ductal Carcinoma In Situ (DCIS).
CPS+EG Score
Estimates prognosis after neoadjuvant chemotherapy.
Allred Score for ER/PR
Standard scoring system for Estrogen (ER) and Progesterone (PR) hormone receptors.
Magee Equation (Est. Oncotype DX®)
Estimates the Oncotype DX® Recurrence Score using standard pathology data.
AJCC Prognostic Stage (Breast)
Anatomic TNM staging with prognostic biomarker recording.
Residual Cancer Burden (RCB)
Quantifies residual disease after neoadjuvant chemotherapy.
PREDICT Breast (Prognostic Index)
Estimates prognosis using the PREDICT v2.1/2.2 model parameters.
Gail Model (Relative Risk)
Estimates relative risk of developing invasive breast cancer.
Oncotype DX Interpreter
Interprets Recurrence Score (RS) based on TAILORx and RxPONDER trials.
MammaPrint Interpreter
Interprets MammaPrint (70-gene signature) results (High vs Low Risk).
Prosigna / PAM50 Interpreter
Interprets PAM50 ROR Score for recurrence risk.
EndoPredict (EPclin) Interpreter
Interprets EPclin Score for early and late recurrence risk.
Breast Cancer Index (BCI)
Predicts benefit from Extended Endocrine Therapy (EET).
D'Amico Risk Classification
Stratifies prostate cancer recurrence risk (Low, Intermediate, High).
Epstein Criteria (Insignificant Cancer)
Predicts clinically insignificant prostate cancer suitable for Active Surveillance.
PI-RADS™ v2.1 (Prostate MRI)
Prostate Imaging Reporting and Data System for MRI assessment.
Gleason Score & ISUP Grade
Converts Gleason patterns into ISUP Grade Groups (1-5).
CAPRA Score
Cancer of the Prostate Risk Assessment (UCSF) score.
CAPRA-S Score (Post-Surgical)
Predicts recurrence after radical prostatectomy (Pathologic data).
Decipher® Prostate Risk
Interprets genomic classifier score for metastasis risk.
Prolaris® (CCP Score)
Assess tumor aggressiveness via Cell Cycle Progression (CCP) genes.
Oncotype DX® GPS (Prostate)
Genomic Prostate Score (GPS) for tumor aggressiveness.
ProMark® Proteomic Score
Proteomic prediction of aggressive prostate cancer behavior.
EORTC Risk Tables (NMIBC)
Predicts recurrence and progression in Non-Muscle Invasive Bladder Cancer.
CUETO Risk Score (BCG-Treated)
Predicts recurrence and progression in NMIBC patients treated with BCG.
EAU NMIBC Risk Stratification (2024)
Current EAU guideline risk groups (Low, Intermediate, High, Very High).
IGCCCG Risk Classification (2021 Update)
Prognostic staging for metastatic germ cell tumors (Modern Era).
MSKCC Stage I NSGCT Nomogram
Predicts occult disease in Clinical Stage I Non-Seminoma.
FIGO GTN Risk Score
Stratifies risk for Gestational Trophoblastic Neoplasia.
RMI (Risk of Malignancy Index)
Estimates malignancy risk in adnexal masses.
ROMA Score (Ovarian)
Risk of Ovarian Malignancy Algorithm (HE4 + CA125).
AGO Score (DESKTOP)
Predicts resectability in recurrent ovarian cancer (Secondary Cytoreduction).
iMODEL (Ovarian Recurrence)
Predicts complete resection at secondary cytoreduction.
O-RADS™ (Ultrasound)
Ovarian-Adnexal Reporting and Data System (ACR v2022).
ESGO/ESTRO/ESP Endometrial Risk (2021)
Risk stratification for Endometrial Cancer (2021 Guidelines).
Mayo Criteria (Endometrial)
Predicts lymph node metastasis in endometrial cancer (surgical staging).
Sedlis Criteria (Cervical)
Identifies intermediate risk factors for adjuvant radiation in cervical cancer.
Moore Criteria (Advanced Cervical)
Prognostic factors for recurrent/metastatic cervical cancer (GOG 110/169/179).
Sentinel Lymph Node Risk (Melanoma)
Predicts risk of sentinel lymph node metastasis in thin/intermediate melanoma.
MACIS Score (Thyroid)
Prognostic score for Papillary Thyroid Carcinoma (PTC).
ATA Risk Stratification (Thyroid)
Predicts risk of recurrence in Differentiated Thyroid Cancer (DTC).
About OncoToolkit: Your Comprehensive Oncology Calculator Resource
OncoToolkit provides healthcare professionals with a comprehensive suite of evidence-based oncology calculators, staging systems, and prognostic tools. Our platform supports clinical decision-making across all major cancer types, from initial diagnosis through treatment planning and follow-up care.
Comprehensive Cancer Staging & Prognosis Tools
Access validated scoring systems including ECOG and Karnofsky Performance Status for functional assessment, Child-Pugh and ALBI scores for liver function evaluation, and tumor-specific staging calculators following AJCC/UICC guidelines. Our tools cover breast cancer (Oncotype DX, NPI), prostate cancer (Gleason, CAPRA), lung cancer (TNM staging, GPA), and many more.
Treatment Decision Support
Make informed treatment decisions with calculators designed to assess treatment eligibility, predict response, and evaluate toxicity risk. From chemotherapy dosing based on BSA calculations to immunotherapy eligibility assessment, our tools help optimize patient outcomes while minimizing adverse events.
Evidence-Based Clinical Tools
Every calculator on OncoToolkit is based on peer-reviewed research and validated in clinical practice. We provide transparent methodology with references to original publications, ensuring you understand the evidence behind each tool. Explore our oncology glossary for terminology definitions and video tutorials about how to use this app.
OncoToolkit is for educational and clinical decision support purposes only. Always verify results with current clinical guidelines and institutional protocols.